Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
- None.
- None.
Initial study in the neoadjuvant setting designed to assess
“We are excited to enter into this collaboration with Incyte to explore the use of
“We look forward to collaborating with Replimune on this study evaluating INCB99280 and
Under the terms of the agreement, Incyte will initiate and sponsor the clinical trial of INCB99280 and
About
About INCB99280
INCB99280 is a potent and selective small molecule oral PD-L1 inhibitor, which has demonstrated promising clinical activity and safety in patients with solid tumors. INCB99280 is being evaluated in multiple Phase 2 studies as monotherapy and in combination with other antitumor agents.
About Replimune
Replimune Group, Inc., headquartered in
About Incyte
Incyte is a
Replimune Forward-looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about the design and advancement of our clinical trials, those of our collaboration partners or the combined clinical trials with our collaboration partners, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our RPx product candidates or those of, or combined with, our collaboration partners, our goals to develop and commercialize our RPx product candidates alone or with our collaboration partners, patient enrollments in our planned clinical trials, alone or with our collaboration partners, and the timing thereof, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our RPx product candidates, alone or with our collaboration partners, changes in laws and regulations to which we are subject, political and global macro factors, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results and the actual results of our collaboration partners and/or the combined results with our collaboration partners could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Incyte Forward-looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential of INCB99280 and/or
These forward-looking statements are based on Incyte’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by regulatory authorities; Incyte’s dependence on its relationships with its collaboration partners; the efficacy or safety of Incyte’s products and the products of Incyte’s collaboration partners; the acceptance of Incyte’s products and the products of Incyte‘s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended March 31, 2023. Incyte disclaims any intent or obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230731698519/en/
Replimune Contacts:
Media
Arleen Goldenberg
Replimune
media@replimune.com
Tel 917.548.1582
Investors
Chris Brinzey
Westwicke, an ICR Company
chris.brinzey@westwicke.com
Tel 339.970.2843
Incyte Contacts:
Media
Catalina Loveman
cloveman@incyte.com
Tel 302.498.6171
Investors
Greg Shertzer
gshertzer@incyte.com
Tel 302.498.4779
Source: Incyte
FAQ
What is the collaboration between Replimune Group, Inc. and Incyte about?
What is the potential of the RPx platform highlighted in the collaboration?
What is the goal of exploring the use of RP1 with Incyte’s oral PD-L1 inhibitor?